{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:35:45Z","timestamp":1790516145827,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.juro.2013.08.082","type":"journal-article","created":{"date-parts":[[2013,9,7]],"date-time":"2013-09-07T15:15:59Z","timestamp":1378566959000},"page":"253-260","source":"Crossref","is-referenced-by-count":33,"title":["Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder Syndrome"],"prefix":"10.1097","volume":"191","author":[{"given":"C.R.","family":"Chapple","sequence":"first","affiliation":[{"name":"Royal Hallamshire Hospital, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Southmead Hospital, Bristol Urological Institute, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-E.","family":"Andersson","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Radziszewski","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Masuda","sequence":"additional","affiliation":[{"name":"ONO Pharma Ltd., London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Small","sequence":"additional","affiliation":[{"name":"ONO Pharma Ltd., London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kuwayama","sequence":"additional","affiliation":[{"name":"ONO Pharma Ltd., London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Deacon","sequence":"additional","affiliation":[{"name":"ONO Pharma Ltd., London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.08.082_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2013.08.082_bib2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-3-642-16499-6_16","article-title":"Muscarinic acetylcholine receptors in the urinary tract","volume":"202","author":"Andersson","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.juro.2013.08.082_bib4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","article-title":"Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?","volume":"98","author":"Finney","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.08.082_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1464-410X.2008.07769.x","article-title":"A review of adherence to drug therapy in patients with overactive bladder","volume":"102","author":"Basra","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.08.082_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.juro.2009.11.026","article-title":"Overactive bladder medication adherence when medication is free to patients","volume":"183","author":"Sears","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib8","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.08.082_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/pr.56.4.4","article-title":"Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence","volume":"56","author":"Andersson","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.juro.2013.08.082_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00300786","article-title":"Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study","volume":"18","author":"Sch\u00fcssler","year":"1990","journal-title":"Urol Res"},{"key":"10.1016\/j.juro.2013.08.082_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1464-410X.1981.tb03183.x","article-title":"The value of intravesical prostaglandin E2 and F2 alpha in women with abnormalities of bladder emptying","volume":"53","author":"Delaere","year":"1981","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1464-410X.2004.04563.x","article-title":"Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity","volume":"93","author":"Hindley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.08.082_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1442-2042.2005.01140.x","article-title":"Changes of urinary nerve growth factor and prostaglandins in male subjects with overactive bladder symptom","volume":"12","author":"Kim","year":"2005","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib14","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0022-5347(05)00992-4","article-title":"Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder","volume":"175","author":"Kim","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1569-9056(10)60766-X","article-title":"Urinary prostaglandin E2 levels are elevated in patients with overactive bladder and painful bladder syndrome and correlate with bladder diary symptoms","volume":"9","author":"Abrams","year":"2010","journal-title":"Eur Urol, suppl."},{"key":"10.1016\/j.juro.2013.08.082_bib16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/01.ju.0000134186.58854.2c","article-title":"Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice","volume":"172","author":"Schr\u00f6der","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.juro.2006.11.070","article-title":"Urodynamic effects of a novel EP(1) receptor antagonist in normal rats and rats with bladder outlet obstruction","volume":"177","author":"Lee","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1569-9056(10)60130-3","article-title":"ONO-8539, a novel EP1 receptor antagonist, suppresses bladder hyperactivity via excessive production of prostaglandin E2 (PGE2) induced by intravesical instillation of ATP in urodynamic evaluation of cynomolgus monkeys","volume":"9","author":"Okada","year":"2010","journal-title":"Eur Urol, suppl."},{"key":"10.1016\/j.juro.2013.08.082_bib19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1569-9056(10)60760-9","article-title":"Safety, tolerability and pharmacokinetic of multiple ascending doses of the EP-1 receptor antagonist ONO-8539, a potential new and novel therapy to overactive bladder in healthy young and elderly subjects","volume":"9","author":"Wilbraham","year":"2010","journal-title":"Eur Urol, suppl."},{"key":"10.1016\/j.juro.2013.08.082_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/j.juro.2013.08.082_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1023422208910","article-title":"Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder","volume":"12","author":"Reese","year":"2003","journal-title":"Qual Life Res"},{"key":"10.1016\/j.juro.2013.08.082_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1464-410X.1996.93013.x","article-title":"The ICS-\u2018BPH\u2019 study: the psychometric validity and reliability of the ICS male questionnaire","volume":"77","author":"Donovan","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2490-12-26","article-title":"Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder","volume":"12","author":"Notte","year":"2012","journal-title":"BMC Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1043-6618(05)80059-3","article-title":"Prostanoids as local modulators of reflex micturition","volume":"25","author":"Maggi","year":"1992","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.juro.2013.08.082_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2220\/biomedres.27.49","article-title":"Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats","volume":"27","author":"Ikeda","year":"2006","journal-title":"Biomed Res"},{"key":"10.1016\/j.juro.2013.08.082_bib26","first-page":"F129","article-title":"Obstruction stimulates COX-2 expression in bladder smooth muscle cells via increased mechanical stretch","volume":"276","author":"Park","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.juro.2013.08.082_bib27","doi-asserted-by":"crossref","first-page":"1267.e13","DOI":"10.1016\/j.urology.2010.06.012","article-title":"Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome","volume":"76","author":"Yamauchi","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.08.082_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0090-4295(01)01637-5","article-title":"Bladder activation: afferent mechanisms","volume":"59","author":"Andersson","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.08.082_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2010.03.147","article-title":"A Multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder","volume":"184","author":"Frenkl","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.08.082_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/nau.20300","article-title":"Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: a single dose, 4 weeks, double-blind, randomized, placebo controlled trial","volume":"26","author":"Rios","year":"2007","journal-title":"Neurourol Urodyn"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713053299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713053299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.08.082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T23:34:06Z","timestamp":1651188846000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.08.082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1016\/j.juro.2013.08.082"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.08.082","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718104192.793485450","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718104192.793485647","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718104192.793488919","asserted-by":"object"}]},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}